Multispectral Optoacoustic Tomography in Patients With Cystic Fibrosis

NCT ID: NCT06063785

Last Updated: 2023-10-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-01

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cystic fibrosis (CF) is the most common hereditary disease in Central Europe. The disease is caused by a mutation in the cystic fibrosis transmembrane conductance regulator gene (CFTR). In the liver, fibrotic remodeling can lead to liver cirrhosis in the long term. Early detection of CF hepatopathy is essential to therapeutically slow down the progression of fibrotic remodeling mechanisms. Newborns suffering from CF have a significantly increased risk for the occurrence of meconium ileus and also with advancing age there are symptoms ranging from chronic constipation to Distal Intestinal Obstruction Syndrome (DIOS), due to a reduction of intestinal motility.

In this study, the degree of liver fibrosis will now be investigated in adult patients with cystic fibrosis using Multispectral Optoacoustic Imaging (MSOT). In addition, gastrointestinal passage will be studied non-invasively to investigate another affection of the gastrointestinal system.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cystic fibrosis (CF) is the most common hereditary disease in Central Europe, with an incidence of approximately 3,300 to 4,800 new cases. The disease follows an autosomal recessive pattern of inheritance, the cause being a mutation in the cystic fibrosis transmembrane conductance regulator gene (CFTR). In the liver, fibrotic remodeling can lead to liver cirrhosis in the long term. Early detection of CF hepatopathy is essential to therapeutically slow down the progression of fibrotic remodeling mechanisms. Over the past decade, measurements of liver stiffness using Acoustic Radiation Force Impulse Imaging (ARFI) have proven to be a valid tool for measuring fibrotic tissue remodeling in CF in adults and children. Furthermore, in the gastrointestinal tract, serious consequences result from the absence of the CFTR channel. Newborns suffering from CF have a significantly increased risk for the occurrence of meconium ileus and also with advancing age there are symptoms ranging from chronic constipation to DIOS (Distal Intestinal Obstruction Syndrome), due to a reduction of intestinal motility.

By means of new imaging methods, such as multispectral optoacoustic tomography, it is possible to examine not only the body's own substances but also substances foreign to the body. With Multispectral Optoacoustic Imaging (MSOT), similar to conventional sonography, a transducer is placed on the skin and instead of sound, energy is applied to the tissue by means of light flashes. This leads to a constant alternation of minimal expansions and contractions (thermoelastic expansion) of individual tissue components or molecules. Previous studies have shown that quantitative determination of hemoglobin can provide information on blood flow and inflammatory activity in the intestines of adult patients with Crohn's disease. Also, fibrotic changes in the liver can probably be detected with this method, similar to that in muscle tissue. Furthermore, we have recently shown that orally ingested Indocyanine green (ICG) can be detected in the small intestine and thus conclusions can be drawn about gastrointestinal passage, without the use of ionizing radiation. In this study, the degree of liver fibrosis will now be investigated in adult patients with cystic fibrosis using MSOT. In addition, gastrointestinal passage will be studied non-invasively to investigate another affection of the gastrointestinal system.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis Liver Fibrosis Gastrointestinal Transport Disorder Dios

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CF with liver affection

CF patients with proven CF hepatopathy

Acoustic Radiation Forced Impulse Imaging

Intervention Type DIAGNOSTIC_TEST

Measurement of Liver stiffness

Multispectral Optoacoustic Tomography

Intervention Type DIAGNOSTIC_TEST

Measurement of optoacoustic spectra in liver and gastrointestinal tract

CF without liver affection

CF patients without proven CF hepatopathy

Acoustic Radiation Forced Impulse Imaging

Intervention Type DIAGNOSTIC_TEST

Measurement of Liver stiffness

Multispectral Optoacoustic Tomography

Intervention Type DIAGNOSTIC_TEST

Measurement of optoacoustic spectra in liver and gastrointestinal tract

Healthy volunteers

Healthy volunteers without liver affection

Acoustic Radiation Forced Impulse Imaging

Intervention Type DIAGNOSTIC_TEST

Measurement of Liver stiffness

Multispectral Optoacoustic Tomography

Intervention Type DIAGNOSTIC_TEST

Measurement of optoacoustic spectra in liver and gastrointestinal tract

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acoustic Radiation Forced Impulse Imaging

Measurement of Liver stiffness

Intervention Type DIAGNOSTIC_TEST

Multispectral Optoacoustic Tomography

Measurement of optoacoustic spectra in liver and gastrointestinal tract

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ARFI MSOT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patient cohort "Cystic Fibrosis without CF-related liver disease":

* Molecular genetic confirmed diagnosis of cystic fibrosis.
* Age over 18 years
* Written informed consent

Patient cohort "Cystic Fibrosis with CF-related liver disease":

* Molecular genetic confirmed diagnosis of cystic fibrosis
* Presence of CF-related liver disease based on Colombo criteria:

* Hepato- and/or splenomegaly
* Persistent elevation of transaminases in the serum
* Sonographic evidence of liver involvement
* Age over 18 years
* Written informed consent

"Volunteer Subjects":

* Age over 18 years
* Written informed consent

Exclusion Criteria

General:

* Pregnancy
* Breastfeeding mothers
* Tattoo in the area of the examination
* Subcutaneous fat tissue over 3 cm

Patient cohort "Cystic fibrosis without CF-related liver disease":

* Taking systemic glucocorticoids or immunosuppressants as part of a permanent medication regimen.
* Presence of CF-related liver disease based on Colombo criteria:

* Hepato- and/or splenomegaly.
* Persistent elevation of transaminases in the serum
* Sonographic evidence of liver involvement.
* Acute exacerbation of infection

Patient cohort "Cystic fibrosis with CF-related liver disease":

* Taking systemic glucocorticoids or immunosuppressants as part of a permanent medication regimen.
* Decompensation of CF-related liver disease
* Acute exacerbation of infection

"volunteer subjects":

* Presence of liver disease
* Use of systemic glucocorticoids or immunosuppressants in the context of permanent medication
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Adrian Regensburger

UNKNOWN

Sponsor Role collaborator

University of Erlangen-Nürnberg Medical School

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alexander Schnell

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alexander Schnell

Role: PRINCIPAL_INVESTIGATOR

Department of Pediatric and Adolescent Medicine, University Hospital Erlangen

Adrian P Regensburger

Role: PRINCIPAL_INVESTIGATOR

Department of Pediatric and Adolescent Medicine, University Hospital Erlangen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Erlange, Department of Pediatrics

Erlangen, Bavaria, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alexander Schnell

Role: CONTACT

+4991318533118

Adrian P Regensburger

Role: CONTACT

+4991318533118

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alexander Schnell, Dr. med.

Role: primary

+4991318533118

Adrian P Regensburger, PD Dr. med.

Role: backup

+4991318533118

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CF_MSOT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Regional Monitoring of CF Lung Disease
NCT06339593 RECRUITING EARLY_PHASE1